Antiangiogenic Treatment with the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein in an Orthotopic Human Pancreatic Cancer Model
Open Access
- 15 March 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (6) , 2337-2344
- https://doi.org/10.1158/1078-0432.ccr-04-1900
Abstract
Purpose: This study investigates the antiangiogenesis and antitumor efficacy of a recombinant protein composed of the three type 1 repeats (3TSR) of thrombospondin-1 in an orthotopic human pancreatic cancer model and provides useful preclinical data for pancreatic cancer treatment.Keywords
This publication has 37 references indexed in Scilit:
- Thrombospondin-1-induced vascular smooth muscle cell chemotaxis: The role of the type 3 repeat and carboxyl terminal domainsJournal of Cellular Biochemistry, 2003
- RETRACTED: Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesisCancer Cell, 2003
- Effect of the vascular endothelial growth factor receptor‐2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude miceInternational Journal of Cancer, 2002
- Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growthJournal of Cellular and Molecular Medicine, 2002
- Thrombospondin-1 Gene Expression Affects Survival and Tumor Spectrum of p53-Deficient MiceThe American Journal of Pathology, 2001
- In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effectsGenes & Development, 2001
- The application of an antiangiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenograftsCancer Gene Therapy, 2000
- The Hallmarks of CancerCell, 2000
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisPublished by Elsevier ,1996
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971